amiratx.com
  • Home
  • AMI463
  • Pipeline
  • Partners
  • Resources
  • Contact
Select Page

Amira Therapeutics Receives Orphan Drug Designation for AMI463 in Soft Tissue Sarcoma in the United States

by Sergi | Apr 9, 2024 | Press Releases

Amira Therapeutics Receives Orphan Drug Designation for AMI463 in Soft Tissue Sarcoma in the United States Amira therapeutics has received orphan drug designation (ODD) for its compound AMI463 by the FDA. The compound had previously received the designation of rare...

Recent Posts

  • Amira Therapeutics Receives Orphan Drug Designation for AMI463 in Soft Tissue Sarcoma in the United States
  • Cell biology of protein–lipid conjugation
  • Targeting the Hedgehog Pathway in Rhabdomyosarcoma
  • RCAN1-mediated calcineurin inhibition as a target for cancer therapy
  • Recent knowledge of NFATc4 in oncogenesis and cancer prognosis

Recent Comments

No comments to show.

Privacy Policy

Legal Notice

Cookie Policy

Related Publications

  • 2024
  • 2023
  • 2022
Ready to help children beat cancer
  • X
  • RSS
© 2023 Amira Therapeutics, SL